KCNA2 IgG autoimmunity in neuropsychiatric diseases
Friederike A. Arlt,Ramona Miske,Marie-Luise Machule,Peter Broegger Christensen,Swantje Mindorf,Bianca Teegen,Kathrin Borowski,Maria Buthut,Rosa Rößling,Elisa Sanchez-Sendin,Scott van Hoof,César Cordero-Gómez,Isabel Bünger,Helena Radbruch,Andrea Kraft,Ilya Ayzenberg,Jaqueline Klausewitz,Niels Hansen,Charles Timäus,Peter Körtvelyessy,Thomas Postert,Kirsten Baur-Seack,Constanze Rost,Robert Brunkhorst,Kathrin Doppler,Niklas Haigis,Gerhard Hamann,Albrecht Kunze,Alexandra Stützer,Matthias Maschke,Nico Melzer,Felix Rosenow,Kai Siebenbrodt,Christian Stenør,Martin Dichgans,Marios K. Georgakis,Rong Fang,Gabor C. Petzold,Michael Görtler,Inga Zerr,Silke Wunderlich,Ivan Mihaljevic,Paul Turko,Marianne Schmidt Ettrup,Emilie Buchholz,Helle Foverskov Rasmussen,Mahoor Nasouti,Ivan Talucci,Hans M. Maric,Stefan H. Heinemann,Matthias Endres,Lars Komorowski,Harald Prüss
DOI: https://doi.org/10.1016/j.bbi.2024.01.220
IF: 19.227
2024-02-05
Brain Behavior and Immunity
Abstract:CONCLUSION: Our data suggest that KCNA2 autoimmunity is clinically heterogeneous. Future studies should determine whether KCNA2 autoantibodies are directly pathogenic or develop secondarily. Early immunotherapy should be considered, in particular if autoantibodies occur in CSF or if clinical or diagnostic findings suggest ongoing inflammation. Suspicious clinical phenotypes include autoimmune encephalitis, atypical dementia, new-onset epilepsy and unexplained epileptic seizures.
immunology,neurosciences,psychiatry